糖尿病網膜症治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21APR1838)
◆英語タイトル:Global Diabetic Retinopathy Drugs Market Size, Status and Forecast 2021-2027
◆商品コード:QY21APR1838
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年4月
◆ページ数:98
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥526,500見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥789,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、糖尿病網膜症治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(ルセンティス、オプチナ、イルビエン、ベータメタゾン、オズルデックス、その他)、用途別市場規模(50〜60歳、60〜70歳、その他)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・糖尿病網膜症治療薬の市場動向
・企業の競争状況、市場シェア
・糖尿病網膜症治療薬の種類別市場規模(ルセンティス、オプチナ、イルビエン、ベータメタゾン、オズルデックス、その他)
・糖尿病網膜症治療薬の用途別市場規模(50〜60歳、60〜70歳、その他)
・糖尿病網膜症治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・糖尿病網膜症治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・糖尿病網膜症治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・糖尿病網膜症治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・糖尿病網膜症治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Novartis、Bayer Healthcare、Roche、Neurotech Pharmaceuticals、Regeneron Pharmaceuticals、Allergan)
・結論
【レポートの概要】

Diabetic retinopathy is an ophthalmic disorder, in which blindness occurrs due to complications in diabetes.
The North American region is the most lucrative market, owing to large number of elderly population in the U.S. However, European and Asia-Pacific regions are considered as the most promising markets in the upcoming period.

Market Analysis and Insights: Global Diabetic Retinopathy Drugs Market
The global Diabetic Retinopathy Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Diabetic Retinopathy Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Diabetic Retinopathy Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Diabetic Retinopathy Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Diabetic Retinopathy Drugs market.

Global Diabetic Retinopathy Drugs Scope and Market Size
Diabetic Retinopathy Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Diabetic Retinopathy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Lucentis
Optina
Iluvien
Betamethazone
Ozurdex
Other

Segment by Application
50-60 Years Old
60-70 Years Old
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Novartis
Bayer Healthcare
Roche
Neurotech Pharmaceuticals
Regeneron Pharmaceuticals
Allergan

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Diabetic Retinopathy Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Lucentis
1.2.3 Optina
1.2.4 Iluvien
1.2.5 Betamethazone
1.2.6 Ozurdex
1.2.7 Other
1.3 Market by Application
1.3.1 Global Diabetic Retinopathy Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 50-60 Years Old
1.3.3 60-70 Years Old
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Diabetic Retinopathy Drugs Market Perspective (2016-2027)
2.2 Diabetic Retinopathy Drugs Growth Trends by Regions
2.2.1 Diabetic Retinopathy Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Diabetic Retinopathy Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Diabetic Retinopathy Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Diabetic Retinopathy Drugs Industry Dynamic
2.3.1 Diabetic Retinopathy Drugs Market Trends
2.3.2 Diabetic Retinopathy Drugs Market Drivers
2.3.3 Diabetic Retinopathy Drugs Market Challenges
2.3.4 Diabetic Retinopathy Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Diabetic Retinopathy Drugs Players by Revenue
3.1.1 Global Top Diabetic Retinopathy Drugs Players by Revenue (2016-2021)
3.1.2 Global Diabetic Retinopathy Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Diabetic Retinopathy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Diabetic Retinopathy Drugs Revenue
3.4 Global Diabetic Retinopathy Drugs Market Concentration Ratio
3.4.1 Global Diabetic Retinopathy Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Diabetic Retinopathy Drugs Revenue in 2020
3.5 Diabetic Retinopathy Drugs Key Players Head office and Area Served
3.6 Key Players Diabetic Retinopathy Drugs Product Solution and Service
3.7 Date of Enter into Diabetic Retinopathy Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Diabetic Retinopathy Drugs Breakdown Data by Type
4.1 Global Diabetic Retinopathy Drugs Historic Market Size by Type (2016-2021)
4.2 Global Diabetic Retinopathy Drugs Forecasted Market Size by Type (2022-2027)

5 Diabetic Retinopathy Drugs Breakdown Data by Application
5.1 Global Diabetic Retinopathy Drugs Historic Market Size by Application (2016-2021)
5.2 Global Diabetic Retinopathy Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Diabetic Retinopathy Drugs Market Size (2016-2027)
6.2 North America Diabetic Retinopathy Drugs Market Size by Type
6.2.1 North America Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
6.2.2 North America Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
6.2.3 North America Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
6.3 North America Diabetic Retinopathy Drugs Market Size by Application
6.3.1 North America Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
6.3.2 North America Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
6.3.3 North America Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
6.4 North America Diabetic Retinopathy Drugs Market Size by Country
6.4.1 North America Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
6.4.2 North America Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Diabetic Retinopathy Drugs Market Size (2016-2027)
7.2 Europe Diabetic Retinopathy Drugs Market Size by Type
7.2.1 Europe Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
7.2.2 Europe Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
7.2.3 Europe Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
7.3 Europe Diabetic Retinopathy Drugs Market Size by Application
7.3.1 Europe Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
7.3.2 Europe Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
7.3.3 Europe Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
7.4 Europe Diabetic Retinopathy Drugs Market Size by Country
7.4.1 Europe Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
7.4.2 Europe Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size (2016-2027)
8.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type
8.2.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application
8.3.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region
8.4.1 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Diabetic Retinopathy Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Diabetic Retinopathy Drugs Market Size (2016-2027)
9.2 Latin America Diabetic Retinopathy Drugs Market Size by Type
9.2.1 Latin America Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
9.3 Latin America Diabetic Retinopathy Drugs Market Size by Application
9.3.1 Latin America Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
9.4 Latin America Diabetic Retinopathy Drugs Market Size by Country
9.4.1 Latin America Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size (2016-2027)
10.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type
10.2.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application
10.3.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country
10.4.1 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Diabetic Retinopathy Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Diabetic Retinopathy Drugs Introduction
11.1.4 Novartis Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.1.5 Novartis Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare Diabetic Retinopathy Drugs Introduction
11.2.4 Bayer Healthcare Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.2.5 Bayer Healthcare Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Diabetic Retinopathy Drugs Introduction
11.3.4 Roche Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Neurotech Pharmaceuticals
11.4.1 Neurotech Pharmaceuticals Company Details
11.4.2 Neurotech Pharmaceuticals Business Overview
11.4.3 Neurotech Pharmaceuticals Diabetic Retinopathy Drugs Introduction
11.4.4 Neurotech Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.4.5 Neurotech Pharmaceuticals Recent Development
11.5 Regeneron Pharmaceuticals
11.5.1 Regeneron Pharmaceuticals Company Details
11.5.2 Regeneron Pharmaceuticals Business Overview
11.5.3 Regeneron Pharmaceuticals Diabetic Retinopathy Drugs Introduction
11.5.4 Regeneron Pharmaceuticals Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.5.5 Regeneron Pharmaceuticals Recent Development
11.6 Allergan
11.6.1 Allergan Company Details
11.6.2 Allergan Business Overview
11.6.3 Allergan Diabetic Retinopathy Drugs Introduction
11.6.4 Allergan Revenue in Diabetic Retinopathy Drugs Business (2016-2021)
11.6.5 Allergan Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 糖尿病網膜症治療薬の世界市場規模・現状・予測2021年-2027年(Global Diabetic Retinopathy Drugs Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。